The NIH and the National Institute of Allergy and Infectious Diseases awarded a contract worth $40.7 million to Crucell to develop monoclonal antibodies for influenza as pandemic alert level reaches level six, said Jaap Goudsmit, the company's chief scientific officer. The Dutch biotech firm says the deal could reach up to $69.1 million if the NIH issues additional financing.

Full Story:

Related Summaries